Computational Random Mutagenesis to Investigate RAS Mutant Signaling
Reference28 articles.
1. Mendiratta G, Ke E, Aziz M, Liarakos D, Tong M, Stites EC (2021) Cancer gene mutation frequencies for the U.S. population. Nat Commun 12(1):5961. https://doi.org/10.1038/s41467-021-26213-y 2. Moore AR, Rosenberg SC, McCormick F, Malek S (2020) RAS-targeted therapies: is the undruggable drugged? Nat Rev Drug Discov 19(8):533–552. https://doi.org/10.1038/s41573-020-0068-6 3. Westcott PM, Halliwill KD, To MD, Rashid M, Rust AG, Keane TM, Delrosario R, Jen KY, Gurley KE, Kemp CJ, Fredlund E, Quigley DA, Adams DJ, Balmain A (2015) The mutational landscapes of genetic and chemical models of Kras-driven lung cancer. Nature 517(7535):489–492. https://doi.org/10.1038/nature13898 4. Pershing NL, Lampson BL, Belsky JA, Kaltenbrun E, MacAlpine DM, Counter CM (2015) Rare codons capacitate Kras-driven de novo tumorigenesis. J Clin Invest 125(1):222–233. https://doi.org/10.1172/JCI77627 5. Krengel U, Schlichting I, Scherer A, Schumann R, Frech M, John J, Kabsch W, Pai EF, Wittinghofer A (1990) Three-dimensional structures of H-ras p21 mutants: molecular basis for their inability to function as signal switch molecules. Cell 62(3):539–548. https://doi.org/10.1016/0092-8674(90)90018-a
|
|